Cargando…

Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimer’s disease

BACKGROUND: The LipiDiDiet trial showed that Souvenaid, a medical food, might delay progression to dementia in prodromal Alzheimer’s disease (AD). The objective of this study was to assess the cost-utility of Souvenaid compared to placebo in patients with prodromal AD under the conditions applied in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mar, Javier, Gorostiza, Ania, Ibarrondo, Oliver, Larrañaga, Igor, Arrospide, Arantzazu, Martinez-Lage, Pablo, Soto-Gordoa, Myriam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731786/ https://www.ncbi.nlm.nih.gov/pubmed/33308302 http://dx.doi.org/10.1186/s13195-020-00737-9

Ejemplares similares

Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain
por: Mar, Javier, et al.
Publicado: (2022)

Fitting the epidemiology and neuropathology of the early stages of Alzheimer’s disease to prevent dementia
por: Mar, Javier, et al.
Publicado: (2015)

Validation of Random Forest Machine Learning Models to Predict Dementia-Related Neuropsychiatric Symptoms in Real-World Data
por: Mar, Javier, et al.
Publicado: (2020)

Development and Validation of a Discrete Event Simulation Model to Evaluate the Cardiovascular Impact of Population Policies for Obesity
por: Arrospide, Arantzazu, et al.
Publicado: (2021)

Impacto de la identificación de pacientes en un programa de cuidados paliativos del País Vasco
por: Larrañaga, Igor, et al.
Publicado: (2019)

Excess healthcare costs of mental disorders in children, adolescents and young adults in the Basque population registry adjusted for socioeconomic status and sex
por: Larrañaga, Igor, et al.
Publicado: (2023)

Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis
por: Arrospide, Arantzazu, et al.
Publicado: (2016)

Dementia-related neuropsychiatric symptoms: inequalities in pharmacological treatment and institutionalization
por: Mar, Javier, et al.
Publicado: (2019)

Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

The impact of acquired brain damage in terms of epidemiology, economics and loss in quality of life
por: Mar, Javier, et al.
Publicado: (2011)

Efficacy of Souvenaid(®) Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer’s Disease
por: García-Alberca, José María, et al.
Publicado: (2023)

Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model
por: Arrospide, Arantzazu, et al.
Publicado: (2018)

Inequalities in health-related quality of life according to age, gender, educational level, social class, body mass index and chronic diseases using the Spanish value set for Euroquol 5D-5L questionnaire
por: Arrospide, Arantzazu, et al.
Publicado: (2019)

Impact of disability on different domains of health-related quality of life in the noninstitutionalized general population
por: Mar, Javier, et al.
Publicado: (2010)

The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease
por: Shah, Raj C, et al.
Publicado: (2013)

Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
por: Rijpma, Anne, et al.
Publicado: (2015)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Souvenaid in the management of mild cognitive impairment: an expert consensus opinion
por: Cummings, Jeffrey, et al.
Publicado: (2019)

The Effect of Souvenaid on Functional Brain Network Organisation in Patients with Mild Alzheimer’s Disease: A Randomised Controlled Study
por: de Waal, Hanneke, et al.
Publicado: (2014)

Evaluation of health benefits and harms of the breast cancer screening programme in the Basque Country using discrete event simulation
por: Arrospide, Arantzazu, et al.
Publicado: (2015)

The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer’s disease: results from a randomized controlled trial
por: Rijpma, Anne, et al.
Publicado: (2017)

Time Perception in Prodromal Alzheimer's Dementia and in Prodromal Dementia With Lewy Bodies
por: Pai, Ming-Chyi, et al.
Publicado: (2021)

Assessment of a Potential Synergistic Effect of Souvenaid(®) in Mild Alzheimer’s Disease Patients on Treatment with Acetylcholinesterase Inhibitors: An Observational, Non-Interventional Study
por: Viñuela, Félix, et al.
Publicado: (2021)

Inflammaging as a prodrome to Alzheimer's disease
por: Giunta, Brian, et al.
Publicado: (2008)

Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011)

36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease
por: Soininen, Hilkka, et al.
Publicado: (2020)

Evaluation of choroidal thickness in prodromal Alzheimer’s disease defined by amyloid PET
por: López-de-Eguileta, Alicia, et al.
Publicado: (2020)

Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer’s disease
por: Nakamura, Akinori, et al.
Publicado: (2018)

Ganglion cell layer thinning in prodromal Alzheimer's disease defined by amyloid PET
por: López-de-Eguileta, Alicia, et al.
Publicado: (2019)

Brainstem substructures and cognition in prodromal Alzheimer’s disease
por: Dutt, Shubir, et al.
Publicado: (2021)

Involvement of mirror neuron system in prodromal Alzheimer's disease
por: Moretti, D.V.
Publicado: (2016)

Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias
por: King, Eleanor, et al.
Publicado: (2018)

Targeting prodromal Alzheimer’s disease: too late for prevention?
por: Yassine, Hussein N
Publicado: (2017)

Impaired perfusion and capillary dysfunction in prodromal Alzheimer's disease
por: Nielsen, Rune B., et al.
Publicado: (2020)

A Case of Minimally Progressive Prodromal Alzheimer’s Disease
por: Rosenbloom, Michael H., et al.
Publicado: (2023)

Detecting Anosognosia from the Prodromal Stage of Alzheimer’s Disease
por: Guieysse, Thomas, et al.
Publicado: (2023)

An assessment of existing models for individualized breast cancer risk estimation in a screening program in Spain
por: Arrospide, Arantzazu, et al.
Publicado: (2013)

Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans
por: Manzano Palomo, Maria Sagrario, et al.
Publicado: (2019)

Prodromal Alzheimer’s Disease: Constitutive Upregulation of Neuroglobin Prevents the Initiation of Alzheimer’s Pathology
por: de Vidania, Silvia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rhgf90if63hsh1hvk0kd3kg2ds